MAIA Biotechnology to Participate in H.C. Wainwright 24th Annual Global Investment Conference

Rhea-AI Summary

MAIA Biotechnology, Inc. (NYSE American: MAIA) will participate in the H.C. Wainwright 24th Annual Global Investment Conference from September 12-14. The management team is set to present on September 12 at 7:00 am ET and will hold investor meetings until September 14. A webcast of the presentation will be available on the Company's website, with a replay accessible for 30 days post-event. MAIA focuses on developing first-in-class oncology drugs aimed at improving cancer treatment outcomes.

CHICAGO--(BUSINESS WIRE)-- MAIA Biotechnology, Inc., (NYSE American: MAIA) (“MAIA”, the “Company”), a targeted therapy, immuno-oncology company focused on developing potential first-in-class oncology drugs, announced today that the management team will participate in the H.C. Wainwright 24^th Annual Global Investment Conference that will be held September 12^th – 14^th.

The MAIA team is scheduled to present on September 12^th at 7:00 am ET and will host investor meetings at the Conference through September 14^th.

A webcast of the presentation will be available on the News & Events page of the Investors section of the Company's website. A replay of the webcast will be available for 30 days following the event.

About MAIA Biotechnology, Inc.

MAIA is a targeted therapy, immuno-oncology company focused on the development and commercialization of potential first-in-class drugs with novel mechanisms of action that are intended to meaningfully improve and extend the lives of people with cancer. Our lead program is THIO, a potential first-in-class cancer telomere targeting agent in clinical development for the treatment of NSCLC patients with telomerase-positive cancer cells. For more information, please visit www.maiabiotech.com.

Forward Looking Statements

MAIA cautions that all statements, other than statements of historical facts, contained in this press release, are forward-looking statements. Forward-looking statements are subject to known and unknown risks, uncertainties, and other factors that may cause our or our industry’s actual results, levels or activity, performance or achievements to be materially different from those anticipated by such statements. The use of words such as “may,” “might,” “will,” “should,” “could,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “project,” “intend,” “future,” “potential,” or “continue,” and other similar expressions are intended to identify forward looking statements. However, the absence of these words does not mean that statements are not forward-looking. For example, all statements we make regarding (i) the initiation, timing, cost, progress and results of our preclinical and clinical studies and our research and development programs, (ii) our ability to advance product candidates into, and successfully complete, clinical studies, (iii) the timing or likelihood of regulatory filings and approvals, (iv) our ability to develop, manufacture and commercialize our product candidates and to improve the manufacturing process, (v) the rate and degree of market acceptance of our product candidates, (vi) the size and growth potential of the markets for our product candidates and our ability to serve those markets, and (vii) our expectations regarding our ability to obtain and maintain intellectual property protection for our product candidates, are forward looking. All forward-looking statements are based on current estimates, assumptions and expectations by our management that, although we believe to be reasonable, are inherently uncertain. Any forward-looking statement expressing an expectation or belief as to future events is expressed in good faith and believed to be reasonable at the time such forward-looking statement is made. However, these statements are not guarantees of future events and are subject to risks and uncertainties and other factors beyond our control that may cause actual results to differ materially from those expressed in any forward-looking statement. Any forward-looking statement speaks only as of the date on which it was made. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law. In this release, unless the context requires otherwise, “MAIA,” “Company,” “we,” “our,” and “us” refers to MAIA Biotechnology, Inc. and its subsidiaries.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220908005310/en/

MAIA Biotechnology

Joseph McGuire

Chief Financial Officer

jmcguire@maiabiotech.com

904-228-2603



ICR Westwicke

Stephanie Carrington

Stephanie.Carrington@westwicke.com

646-277-1282

Source: MAIA Biotechnology, Inc.

FAQ

When is MAIA Biotechnology presenting at the H.C. Wainwright conference?

MAIA Biotechnology will present on September 12 at 7:00 am ET.

What are the dates for the H.C. Wainwright 24th Annual Global Investment Conference?

The conference will take place from September 12 to September 14.

How can I access the webcast for MAIA's presentation?

The webcast can be accessed on the News & Events page of MAIA's website.

What is the focus of MAIA Biotechnology?

MAIA Biotechnology focuses on developing first-in-class oncology drugs for cancer treatment.

What is the ticker symbol for MAIA Biotechnology?

The ticker symbol for MAIA Biotechnology is MAIA.